APO Research
Talk to an analyst

APO RESEARCH · REPORT

Meningioma Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Meningioma Drug Industry Research Report 2026

22 December 2025121 pages

Choose your research edition.

Industry ResearchMeningioma Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Meningioma Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Meningioma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Meningioma Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Meningioma Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Meningioma Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Meningioma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Meningioma Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Meningioma Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Meningioma Drug include Arno Therapeutics Inc, Boehringer Ingelheim GmbH, Genentech Inc, Merck KGaA, Ono Pharmaceutical Co Ltd, Pharma Mar SA, Progenics Pharmaceuticals Inc, AstraZeneca Plc and GlaxoSmithKline Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Meningioma Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Meningioma Drug Market by Company

Arno Therapeutics Inc

Boehringer Ingelheim GmbH

Genentech Inc

Merck KGaA

Ono Pharmaceutical Co Ltd

Pharma Mar SA

Progenics Pharmaceuticals Inc

AstraZeneca Plc

GlaxoSmithKline Plc

Eli Lilly and Co

Merck & Co Inc

Novartis AG

Meningioma Drug Segment by Type

Avelumab

AR-42

Afatinib Dimaleate

Abemaciclib

Others

Meningioma Drug Segment by Application

Hospital

Clinic

Others

Meningioma Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningioma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Meningioma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningioma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Meningioma Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Meningioma Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Meningioma Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Meningioma Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Meningioma Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Meningioma Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Meningioma Drug Revenue of Manufacturers (2021-2026) Table 9. Global Meningioma Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Meningioma Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Meningioma Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Meningioma Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Meningioma Drug, Product Type & Application Table 14. Global Meningioma Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Meningioma Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Arno Therapeutics Inc Company Information Table 19. Arno Therapeutics Inc Business Overview Table 20. Arno Therapeutics Inc Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Arno Therapeutics Inc Meningioma Drug Product Portfolio Table 22. Arno Therapeutics Inc Recent Developments Table 23. Boehringer Ingelheim GmbH Company Information Table 24. Boehringer Ingelheim GmbH Business Overview Table 25. Boehringer Ingelheim GmbH Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Boehringer Ingelheim GmbH Meningioma Drug Product Portfolio Table 27. Boehringer Ingelheim GmbH Recent Developments Table 28. Genentech Inc Company Information Table 29. Genentech Inc Business Overview Table 30. Genentech Inc Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Genentech Inc Meningioma Drug Product Portfolio Table 32. Genentech Inc Recent Developments Table 33. Merck KGaA Company Information Table 34. Merck KGaA Business Overview Table 35. Merck KGaA Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Merck KGaA Meningioma Drug Product Portfolio Table 37. Merck KGaA Recent Developments Table 38. Ono Pharmaceutical Co Ltd Company Information Table 39. Ono Pharmaceutical Co Ltd Business Overview Table 40. Ono Pharmaceutical Co Ltd Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Ono Pharmaceutical Co Ltd Meningioma Drug Product Portfolio Table 42. Ono Pharmaceutical Co Ltd Recent Developments Table 43. Pharma Mar SA Company Information Table 44. Pharma Mar SA Business Overview Table 45. Pharma Mar SA Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Pharma Mar SA Meningioma Drug Product Portfolio Table 47. Pharma Mar SA Recent Developments Table 48. Progenics Pharmaceuticals Inc Company Information Table 49. Progenics Pharmaceuticals Inc Business Overview Table 50. Progenics Pharmaceuticals Inc Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Progenics Pharmaceuticals Inc Meningioma Drug Product Portfolio Table 52. Progenics Pharmaceuticals Inc Recent Developments Table 53. AstraZeneca Plc Company Information Table 54. AstraZeneca Plc Business Overview Table 55. AstraZeneca Plc Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. AstraZeneca Plc Meningioma Drug Product Portfolio Table 57. AstraZeneca Plc Recent Developments Table 58. GlaxoSmithKline Plc Company Information Table 59. GlaxoSmithKline Plc Business Overview Table 60. GlaxoSmithKline Plc Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. GlaxoSmithKline Plc Meningioma Drug Product Portfolio Table 62. GlaxoSmithKline Plc Recent Developments Table 63. Eli Lilly and Co Company Information Table 64. Eli Lilly and Co Business Overview Table 65. Eli Lilly and Co Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Eli Lilly and Co Meningioma Drug Product Portfolio Table 67. Eli Lilly and Co Recent Developments Table 68. Merck & Co Inc Company Information Table 69. Merck & Co Inc Business Overview Table 70. Merck & Co Inc Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Merck & Co Inc Meningioma Drug Product Portfolio Table 72. Merck & Co Inc Recent Developments Table 73. Novartis AG Company Information Table 74. Novartis AG Business Overview Table 75. Novartis AG Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Novartis AG Meningioma Drug Product Portfolio Table 77. Novartis AG Recent Developments Table 78. Global Meningioma Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 79. Global Meningioma Drug Sales by Region (2021-2026) & (k units) Table 80. Global Meningioma Drug Sales Market Share by Region (2021-2026) Table 81. Global Meningioma Drug Sales by Region (2027-2032) & (k units) Table 82. Global Meningioma Drug Sales Market Share by Region (2027-2032) Table 83. Global Meningioma Drug Revenue by Region (2021-2026) & (US$ Million) Table 84. Global Meningioma Drug Revenue Market Share by Region (2021-2026) Table 85. Global Meningioma Drug Revenue by Region (2027-2032) & (US$ Million) Table 86. Global Meningioma Drug Revenue Market Share by Region (2027-2032) Table 87. North America Meningioma Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. North America Meningioma Drug Sales by Country (2021-2026) & (k units) Table 89. North America Meningioma Drug Sales by Country (2027-2032) & (k units) Table 90. North America Meningioma Drug Revenue by Country (2021-2026) & (US$ Million) Table 91. North America Meningioma Drug Revenue by Country (2027-2032) & (US$ Million) Table 92. Europe Meningioma Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Europe Meningioma Drug Sales by Country (2021-2026) & (k units) Table 94. Europe Meningioma Drug Sales by Country (2027-2032) & (k units) Table 95. Europe Meningioma Drug Revenue by Country (2021-2026) & (US$ Million) Table 96. Europe Meningioma Drug Revenue by Country (2027-2032) & (US$ Million) Table 97. Asia Pacific Meningioma Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Asia Pacific Meningioma Drug Sales by Country (2021-2026) & (k units) Table 99. Asia Pacific Meningioma Drug Sales by Country (2027-2032) & (k units) Table 100. Asia Pacific Meningioma Drug Revenue by Country (2021-2026) & (US$ Million) Table 101. Asia Pacific Meningioma Drug Revenue by Country (2027-2032) & (US$ Million) Table 102. South America Meningioma Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. South America Meningioma Drug Sales by Country (2021-2026) & (k units) Table 104. South America Meningioma Drug Sales by Country (2027-2032) & (k units) Table 105. South America Meningioma Drug Revenue by Country (2021-2026) & (US$ Million) Table 106. South America Meningioma Drug Revenue by Country (2027-2032) & (US$ Million) Table 107. Middle East and Africa Meningioma Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Middle East and Africa Meningioma Drug Sales by Country (2021-2026) & (k units) Table 109. Middle East and Africa Meningioma Drug Sales by Country (2027-2032) & (k units) Table 110. Middle East and Africa Meningioma Drug Revenue by Country (2021-2026) & (US$ Million) Table 111. Middle East and Africa Meningioma Drug Revenue by Country (2027-2032) & (US$ Million) Table 112. Global Meningioma Drug Sales by Type (2021-2026) & (k units) Table 113. Global Meningioma Drug Sales by Type (2027-2032) & (k units) Table 114. Global Meningioma Drug Sales Market Share by Type (2021-2026) Table 115. Global Meningioma Drug Sales Market Share by Type (2027-2032) Table 116. Global Meningioma Drug Revenue by Type (2021-2026) & (US$ Million) Table 117. Global Meningioma Drug Revenue by Type (2027-2032) & (US$ Million) Table 118. Global Meningioma Drug Revenue Market Share by Type (2021-2026) Table 119. Global Meningioma Drug Revenue Market Share by Type (2027-2032) Table 120. Global Meningioma Drug Price by Type (2021-2026) & (US$/unit) Table 121. Global Meningioma Drug Price by Type (2027-2032) & (US$/unit) Table 122. Global Meningioma Drug Sales by Application (2021-2026) & (k units) Table 123. Global Meningioma Drug Sales by Application (2027-2032) & (k units) Table 124. Global Meningioma Drug Sales Market Share by Application (2021-2026) Table 125. Global Meningioma Drug Sales Market Share by Application (2027-2032) Table 126. Global Meningioma Drug Revenue by Application (2021-2026) & (US$ Million) Table 127. Global Meningioma Drug Revenue by Application (2027-2032) & (US$ Million) Table 128. Global Meningioma Drug Revenue Market Share by Application (2021-2026) Table 129. Global Meningioma Drug Revenue Market Share by Application (2027-2032) Table 130. Global Meningioma Drug Price by Application (2021-2026) & (US$/unit) Table 131. Global Meningioma Drug Price by Application (2027-2032) & (US$/unit) Table 132. Key Raw Materials Table 133. Raw Materials Key Suppliers Table 134. Meningioma Drug Distributors List Table 135. Meningioma Drug Customers List Table 136. Meningioma Drug Industry Trends Table 137. Meningioma Drug Industry Drivers Table 138. Meningioma Drug Industry Restraints Table 139. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Meningioma Drug Product Image Figure 5. Global Meningioma Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Meningioma Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Meningioma Drug Sales (2021-2032) & (k units) Figure 8. Global Meningioma Drug Average Price (US$/unit) & (2021-2032) Figure 9. Avelumab Product Image Figure 10. AR-42 Product Image Figure 11. Afatinib Dimaleate Product Image Figure 12. Abemaciclib Product Image Figure 13. Others Product Image Figure 14. Hospital Product Image Figure 15. Clinic Product Image Figure 16. Others Product Image Figure 17. Global Meningioma Drug Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Meningioma Drug, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Meningioma Drug Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Meningioma Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Meningioma Drug Sales by Region in 2025 Figure 23. Global Meningioma Drug Revenue by Region in 2025 Figure 24. North America Meningioma Drug Market Size by Country in 2025 Figure 25. North America Meningioma Drug Sales Market Share by Country (2021-2032) Figure 26. North America Meningioma Drug Revenue Market Share by Country (2021-2032) Figure 27. United States Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Meningioma Drug Market Size by Country in 2025 Figure 31. Europe Meningioma Drug Sales Market Share by Country (2021-2032) Figure 32. Europe Meningioma Drug Revenue Market Share by Country (2021-2032) Figure 33. Germany Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Meningioma Drug Market Size by Country in 2025 Figure 44. Asia Pacific Meningioma Drug Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Meningioma Drug Revenue Market Share by Country (2021-2032) Figure 46. China Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Meningioma Drug Market Size by Country in 2025 Figure 55. South America Meningioma Drug Sales Market Share by Country (2021-2032) Figure 56. South America Meningioma Drug Revenue Market Share by Country (2021-2032) Figure 57. Brazil Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Colombia Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa Meningioma Drug Market Size by Country in 2025 Figure 62. Middle East and Africa Meningioma Drug Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa Meningioma Drug Revenue Market Share by Country (2021-2032) Figure 64. Egypt Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries Meningioma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global Meningioma Drug Sales Market Share by Type (2021-2032) Figure 70. Global Meningioma Drug Revenue Market Share by Type (2021-2032) Figure 71. Global Meningioma Drug Price (US$/unit) by Type (2021-2032) Figure 72. Global Meningioma Drug Sales Market Share by Application (2021-2032) Figure 73. Global Meningioma Drug Revenue Market Share by Application (2021-2032) Figure 74. Global Meningioma Drug Price (US$/unit) by Application (2021-2032) Figure 75. Meningioma Drug Value Chain Figure 76. Meningioma Drug Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Meningioma Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Avelumab
  • AR-42
  • Afatinib Dimaleate
  • Abemaciclib
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Arno Therapeutics Inc
  • Boehringer Ingelheim GmbH
  • Genentech Inc
  • Merck KGaA
  • Ono Pharmaceutical Co Ltd
  • Pharma Mar SA
  • Progenics Pharmaceuticals Inc
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • Eli Lilly and Co
  • Merck & Co Inc
  • Novartis AG

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Meningioma Drug Market Size (2021-2032)
  4. 2.2.2 Global Meningioma Drug Sales (2021-2032)
  5. 2.2.3 Global Meningioma Drug Market Average Price (2021-2032)
  6. 2.3 Meningioma Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Avelumab
  9. 2.3.3 AR-42
  10. 2.3.4 Afatinib Dimaleate
  11. 2.3.5 Abemaciclib
  12. 2.3.6 Others
  13. 2.4 Meningioma Drug by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Hospital
  16. 2.4.3 Clinic
  17. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Meningioma Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Meningioma Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Meningioma Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Meningioma Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Meningioma Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Meningioma Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Meningioma Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Meningioma Drug, Established Date
  9. 3.9 Global Meningioma Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Arno Therapeutics Inc
  2. 4.1.1 Arno Therapeutics Inc Company Information
  3. 4.1.2 Arno Therapeutics Inc Business Overview
  4. 4.1.3 Arno Therapeutics Inc Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Arno Therapeutics Inc Meningioma Drug Product Portfolio
  6. 4.1.5 Arno Therapeutics Inc Recent Developments
  7. 4.2 Boehringer Ingelheim GmbH
  8. 4.2.1 Boehringer Ingelheim GmbH Company Information
  9. 4.2.2 Boehringer Ingelheim GmbH Business Overview
  10. 4.2.3 Boehringer Ingelheim GmbH Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Boehringer Ingelheim GmbH Meningioma Drug Product Portfolio
  12. 4.2.5 Boehringer Ingelheim GmbH Recent Developments
  13. 4.3 Genentech Inc
  14. 4.3.1 Genentech Inc Company Information
  15. 4.3.2 Genentech Inc Business Overview
  16. 4.3.3 Genentech Inc Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Genentech Inc Meningioma Drug Product Portfolio
  18. 4.3.5 Genentech Inc Recent Developments
  19. 4.4 Merck KGaA
  20. 4.4.1 Merck KGaA Company Information
  21. 4.4.2 Merck KGaA Business Overview
  22. 4.4.3 Merck KGaA Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Merck KGaA Meningioma Drug Product Portfolio
  24. 4.4.5 Merck KGaA Recent Developments
  25. 4.5 Ono Pharmaceutical Co Ltd
  26. 4.5.1 Ono Pharmaceutical Co Ltd Company Information
  27. 4.5.2 Ono Pharmaceutical Co Ltd Business Overview
  28. 4.5.3 Ono Pharmaceutical Co Ltd Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Ono Pharmaceutical Co Ltd Meningioma Drug Product Portfolio
  30. 4.5.5 Ono Pharmaceutical Co Ltd Recent Developments
  31. 4.6 Pharma Mar SA
  32. 4.6.1 Pharma Mar SA Company Information
  33. 4.6.2 Pharma Mar SA Business Overview
  34. 4.6.3 Pharma Mar SA Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Pharma Mar SA Meningioma Drug Product Portfolio
  36. 4.6.5 Pharma Mar SA Recent Developments
  37. 4.7 Progenics Pharmaceuticals Inc
  38. 4.7.1 Progenics Pharmaceuticals Inc Company Information
  39. 4.7.2 Progenics Pharmaceuticals Inc Business Overview
  40. 4.7.3 Progenics Pharmaceuticals Inc Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Progenics Pharmaceuticals Inc Meningioma Drug Product Portfolio
  42. 4.7.5 Progenics Pharmaceuticals Inc Recent Developments
  43. 4.8 AstraZeneca Plc
  44. 4.8.1 AstraZeneca Plc Company Information
  45. 4.8.2 AstraZeneca Plc Business Overview
  46. 4.8.3 AstraZeneca Plc Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 AstraZeneca Plc Meningioma Drug Product Portfolio
  48. 4.8.5 AstraZeneca Plc Recent Developments
  49. 4.9 GlaxoSmithKline Plc
  50. 4.9.1 GlaxoSmithKline Plc Company Information
  51. 4.9.2 GlaxoSmithKline Plc Business Overview
  52. 4.9.3 GlaxoSmithKline Plc Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 GlaxoSmithKline Plc Meningioma Drug Product Portfolio
  54. 4.9.5 GlaxoSmithKline Plc Recent Developments
  55. 4.10 Eli Lilly and Co
  56. 4.10.1 Eli Lilly and Co Company Information
  57. 4.10.2 Eli Lilly and Co Business Overview
  58. 4.10.3 Eli Lilly and Co Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Eli Lilly and Co Meningioma Drug Product Portfolio
  60. 4.10.5 Eli Lilly and Co Recent Developments
  61. 4.11 Merck & Co Inc
  62. 4.11.1 Merck & Co Inc Company Information
  63. 4.11.2 Merck & Co Inc Business Overview
  64. 4.11.3 Merck & Co Inc Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Merck & Co Inc Meningioma Drug Product Portfolio
  66. 4.11.5 Merck & Co Inc Recent Developments
  67. 4.12 Novartis AG
  68. 4.12.1 Novartis AG Company Information
  69. 4.12.2 Novartis AG Business Overview
  70. 4.12.3 Novartis AG Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Novartis AG Meningioma Drug Product Portfolio
  72. 4.12.5 Novartis AG Recent Developments
5 Global Meningioma Drug Market Scenario by Region
  1. 5.1 Global Meningioma Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Meningioma Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Meningioma Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Meningioma Drug Sales by Region: 2027-2032
  5. 5.3 Global Meningioma Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Meningioma Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Meningioma Drug Revenue by Region: 2027-2032
  8. 5.4 North America Meningioma Drug Market Facts & Figures by Country
  9. 5.4.1 North America Meningioma Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Meningioma Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Meningioma Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Meningioma Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Meningioma Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Meningioma Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Meningioma Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Meningioma Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Meningioma Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Meningioma Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Meningioma Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Meningioma Drug Market Facts & Figures by Country
  41. 5.7.1 South America Meningioma Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Meningioma Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Meningioma Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Meningioma Drug Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Meningioma Drug Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Meningioma Drug Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Meningioma Drug Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Meningioma Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Meningioma Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Meningioma Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Meningioma Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Meningioma Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Meningioma Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Meningioma Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Meningioma Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Meningioma Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Meningioma Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Meningioma Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Meningioma Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Meningioma Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Meningioma Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Meningioma Drug Value Chain Analysis
  2. 8.1.1 Meningioma Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Meningioma Drug Production Mode & Process
  5. 8.2 Meningioma Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Meningioma Drug Distributors
  8. 8.2.3 Meningioma Drug Customers
9 Global Meningioma Drug Analyzing Market Dynamics
  1. 9.1 Meningioma Drug Industry Trends
  2. 9.2 Meningioma Drug Industry Drivers
  3. 9.3 Meningioma Drug Industry Opportunities and Challenges
  4. 9.4 Meningioma Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst